US20120251548A1 - Treatment of Dermatological Pathologies - Google Patents

Treatment of Dermatological Pathologies Download PDF

Info

Publication number
US20120251548A1
US20120251548A1 US13/437,159 US201213437159A US2012251548A1 US 20120251548 A1 US20120251548 A1 US 20120251548A1 US 201213437159 A US201213437159 A US 201213437159A US 2012251548 A1 US2012251548 A1 US 2012251548A1
Authority
US
United States
Prior art keywords
human
subject
skin inflammation
mabp1
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/437,159
Other languages
English (en)
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Xbiotech USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech USA Inc filed Critical Xbiotech USA Inc
Priority to US13/437,159 priority Critical patent/US20120251548A1/en
Assigned to XBIOTECH, INC. reassignment XBIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIMARD, JOHN
Priority to US13/644,976 priority patent/US9724409B2/en
Publication of US20120251548A1 publication Critical patent/US20120251548A1/en
Priority to US13/928,020 priority patent/US20130287788A1/en
Priority to US15/252,477 priority patent/US9902769B2/en
Priority to US16/112,496 priority patent/US11191831B2/en
Assigned to JANSSEN BIOTECH, INC. reassignment JANSSEN BIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: XBIOTECH INC.
Priority to US17/453,894 priority patent/US20220062413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the invention relates generally to the fields of medicine, dermatology, and immunology. More particularly, the invention relates to the use of antibodies (Abs) which specifically bind interleukin-1 ⁇ (IL-1 60 ) to reduce skin inflammation and to treat inflammatory skin diseases including psoriasis vulgaris and acne vulgaris.
  • Abs antibodies which specifically bind interleukin-1 ⁇ (IL-1 60 ) to reduce skin inflammation and to treat inflammatory skin diseases including psoriasis vulgaris and acne vulgaris.
  • the invention is based on the discovery that a mAb that specifically binds IL-1 ⁇ is useful for reducing skin inflammation as well as treating inflammatory skin diseases including psoriasis vulgaris and acne vulgaris.
  • This discovery was surprising for a number of reasons including previous reports that IL-1 ⁇ levels are reduced in psoriatic skin (e.g., Bonifati et al., J Biol Regul Homeost Agents. 1997 Oct-Dec; 11(4):133-6) and a report implicating anakinra (IL-1 receptor antagonist) as a causative agent in the development of psoriasis (Gonzalez-Lopez et al., British Journal of Dermatology, 158:1146-1148, 2008).
  • the invention features a method of reducing skin inflammation in a human subject.
  • This method can include the step of administering to the subject a pharmaceutical composition including a pharmaceutically acceptable carrier and an amount of an agent that selectively binds IL-1 ⁇ effective to reduce skin inflammation in the subject.
  • the agent can be an anti-IL-1 ⁇ antibody such as a monoclonal antibody (e.g., of the IgG1 isotype), a monoclonal antibody that includes a complementarity determining region of MABp1, or MABp1.
  • the skin inflammation can be associated with acne vulgaris and/or psoriasis vulgaris.
  • one aspect of the invention features a method of reducing skin inflammation in a human subject by administering to the subject a pharmaceutical composition including a pharmaceutically acceptable carrier and an amount of an anti-IL-1 ⁇ Ab (or other agent that specifically and/or selectively binds IL-1 ⁇ ) effective to reduce a symptom of skin inflammation (e.g., redness, swelling, leukocyte infiltration, or lesion development) in the subject by at least about 10% (e.g., at least 8, 9, 10, 15, 17, 20, 30, 40, 50, 60, 70, 80, 90, or 100%) as measured by any standard dermatological test.
  • the anti-IL-1 ⁇ Ab can be a mAb such as an IgG1.
  • the anti-IL-1 ⁇ Ab can be the mAb designated as MABp1 or a mAb that includes one or more complementarity determining regions (CDRs) of MABp1.
  • the skin inflammation can be associated with acne or psoriasis.
  • the pharmaceutical composition can be administered to the subject by injection, subcutaneously, intravenously, intramuscularly, or intradermally. In the method, the dose can be at least 0.25 (e.g., at least 0.2, 0.5, 0.75., 1, 2, 3, 4, or 5) mg/ml.
  • the invention includes use of an agent that selectively binds IL-1 ⁇ to treat skin inflammation in the subject and a pharmaceutical composition for treating skin inflammation in the subject, the composition comprising an agent that selectively binds IL-1 ⁇ .
  • the agent can be an anti-IL-1 ⁇ antibody such as a monoclonal antibody (e.g., of the IgG1 isotype), a monoclonal antibody that includes a complementarity determining region of MABp1, or MABp1; and the skin inflammation can be associated with acne vulgaris and/or psoriasis vulgaris.
  • an “antibody” or “Ab” is an immunoglobulin (Ig), a solution of identical or heterogeneous Igs, or a mixture of Igs.
  • An “Ab” can also refer to fragments and engineered versions of Igs such as Fab, Fab′, and F(ab′) 2 fragments; and scFv's, heteroconjugate Abs, and similar artificial molecules that employ Ig-derived CDRs to impart antigen specificity.
  • a “monoclonal antibody” or “mAb” is an Ab expressed by one clonal B cell line or a population of Ab molecules that contains only one species of an antigen binding site capable of immunoreacting with a particular epitope of a particular antigen.
  • a “polyclonal Ab” is a mixture of heterogeneous Abs.
  • a polyclonal Ab will include myriad different Ab molecules which bind a particular antigen with at least some of the different Abs immunoreacting with a different epitope of the antigen.
  • a polyclonal Ab can be a mixture of two or more mAbs.
  • an “antigen-binding portion” of an Ab is contained within the variable region of the Fab portion of an Ab and is the portion of the Ab that confers antigen specificity to the Ab (i.e., typically the three-dimensional pocket formed by the CDRs of the heavy and light chains of the Ab).
  • a “Fab portion” or “Fab region” is the proteolytic fragment of a papain-digested Ig that contains the antigen-binding portion of that Ig.
  • a “non-Fab portion” is that portion of an Ab not within the Fab portion, e.g., an “Fc portion” or “Fc region.”
  • a “constant region” of an Ab is that portion of the Ab outside of the variable region.
  • effector portion of an Ab, which is the portion of an Ab that is responsible for binding other immune system components that facilitate the immune response.
  • the site on an Ab that binds complement components or Fc receptors is an effector portion of that Ab.
  • purified means separated from components that naturally accompany such molecules.
  • an Ab or protein is purified when it is at least about 10% (e.g., 9%, 10%, 20%, 30% 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 99.9%, and 100%), by weight, free from the non-Ab proteins or other naturally-occurring organic molecules with which it is naturally associated. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. A chemically-synthesized protein or other recombinant protein produced in a cell type other than the cell type in which it naturally occurs is “purified.”
  • bind By “bind”, “binds”, or “reacts with” is meant that one molecule recognizes and adheres to a particular second molecule in a sample, but does not substantially recognize or adhere to other molecules in the sample.
  • an Ab that “specifically binds” another molecule has a K d greater than about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12 liters/mole for that other molecule.
  • An Ab that “selectively binds” a first molecule specifically binds the first molecule at a first epitope but does not specifically bind other molecules that do not have the first epitope.
  • an Ab which selectively binds IL-1alpha specifically binds an epitope on IL-1alpha but does not specifically bind IL-1beta (which does not have the epitope).
  • a “therapeutically effective amount” is an amount which is capable of producing a medically desirable effect in a treated animal or human (e.g., amelioration or prevention of a disease or symptom of a disease).
  • the invention encompasses compositions and methods for reducing skin inflammation including ameliorating one or more symptoms of a dermatological pathology in a subject.
  • the below described preferred embodiments illustrate adaptation of these compositions and methods. Nonetheless, from the description of these embodiments, other aspects of the invention can be made and/or practiced based on the description provided below.
  • Immunological methods for example, assays for detection and localization of antigen-Ab complexes, immunoprecipitation, immunoblotting, and the like
  • methodology treatises such as Current Protocols in Immunology, Coligan et al., ed., John Wiley & Sons, New York.
  • Techniques of molecular biology are described in detail in treatises such as Molecular Cloning: A Laboratory Manual, 2nd ed., vol.
  • compositions and methods described herein are useful for treating skin inflammation (e.g., associated with rosacea, eczema, psoriasis, xerosis, dermatitis, acne, pyoderma gangrenosum, urticaria, lichenoid disorders, bullous diseases such as bullous pemphigoid, cutaneous vasculitis, and granulomatous skin diseases) in a mammalian subject by administering to the subject a pharmaceutical composition including an amount of an anti-IL-1 ⁇ Ab effective to improve at least one characteristic (e.g., reduction in the number or size of lesions, reduction of redness, and reduction in itchiness) of the inflammation in the subject.
  • skin inflammation e.g., associated with rosacea, eczema, psoriasis, xerosis, dermatitis, acne, pyoderma gangrenosum, urticaria, lichenoid disorders, bullous diseases such as bullous pemphi
  • the mammalian subject might be any that suffers from skin inflammation including, human beings, dogs, cats, horses, cattle, sheep, goats, and pigs.
  • Human subjects might be male, female, adults, children, seniors (65 and older), and those with other diseases. Particularly preferred subjects are those whose disease has progressed or failed to respond after treatment with other anti-inflammatory or anti-microbial agents such as retinoids, antibiotics, steroids or cytokine inhibitors such as TNFalpha inhibitors.
  • Subjects who have developed a human anti-human antibody response due to prior administration of therapeutic antibodies are preferred when the anti-IL-1 ⁇ Ab is a true human Ab (e.g., one that is naturally expressed in a human subject) such as MABp1. Any type of inflammatory skin disease susceptible to treatment with an anti-IL-1 ⁇ Ab might be targeted.
  • Anti-IL-1 ⁇ Ab administration is thought to be particularly effective for treating acne vulgaris and psoriasis vulgaris.
  • any suitable type of Ab that specifically binds IL-1 ⁇ and reduces a characteristic of skin inflammation and/or an inflammatory skin disease such as acne vulgaris or psoriasis vulgaris in a subject might be used in the invention.
  • the anti-IL-1 ⁇ Ab used might be mAb, a polyclonal Ab, a mixture of mAbs, or an Ab fragment or engineered Ab-like molecule such as an scFv.
  • the Ka of the Ab is preferably at least 1 ⁇ 10 9 M ⁇ 1 or greater (e.g., greater than 9 ⁇ 10 1 M ⁇ 1 , 8 ⁇ 10 10 M ⁇ 1 , 7 ⁇ 10 10 M ⁇ 1 , 6 ⁇ 10 10 M ⁇ 1 , 5 ⁇ 10 10 M ⁇ 1 , 4 ⁇ 10 10 M ⁇ 1 , 3 ⁇ 10 10 M ⁇ 1 , 2 ⁇ 10 10 M ⁇ 1 , or 1 ⁇ 10 10 M ⁇ 1 ).
  • the invention utilizes a fully human mAb that includes (i) an antigen-binding variable region that exhibits very high binding affinity (e.g., at least nano or picomolar) for human IL-1 ⁇ and (ii) a constant region.
  • the human Ab is preferably an IgG1, although it might be of a different isotype such as IgM, IgA, or IgE, or subclass such as IgG2, IgG3, or IgG4.
  • IgG1 an isotype
  • IgG2 an isotype
  • IgG3 an immunoglobulin G2
  • IgG4 an immunoglobulin G4
  • MABp1 an IL-1 ⁇ -specific IgG1 mAb described in U.S. patent application serial number 12/455,458 filed on Jun. 1, 2009.
  • Other useful mAbs are those that include at least one but preferably all the CDRs of MABp 1 .
  • B lymphocytes which express Ig specific for human IL-1 ⁇ occur naturally in human beings
  • a presently preferred method for raising mAbs is to first isolate such a B lymphocyte from a subject and then immortalize it so that it can be continuously replicated in culture.
  • Subjects lacking large numbers of naturally occurring B lymphocytes which express Ig specific for human IL- 1 ⁇ may be immunized with one or more human IL- 1 ⁇ antigens to increase the number of such B lymphocytes.
  • Human mAbs are prepared by immortalizing a human Ab secreting cell (e.g., a human plasma cell). See, e.g., U.S. Pat. No. 4,634,664.
  • one or more human subjects are screened for the presence of such human IL-1 ⁇ -specific Ab in their blood.
  • Those subjects that express the desired Ab can then be used as B lymphocyte donors.
  • peripheral blood is obtained from a human donor that possesses B lymphocytes that express human IL-1 ⁇ -specific Ab.
  • B lymphocytes are then isolated from the blood sample, e.g., by cells sorting (e.g., fluorescence activated cell sorting, “FACS”; or magnetic bead cell sorting) to select B lymphocytes expressing human IL-1 ⁇ -specific Ig.
  • cells sorting e.g., fluorescence activated cell sorting, “FACS”; or magnetic bead cell sorting
  • the B lymphocytes within this population that express Ig specific for human IL-1 ⁇ can then be isolated by limiting dilution methods (e.g., cells in wells of a microtiter plate that are positive for Ig specific for human IL-1 ⁇ are selected and subcultured, and the process repeated until a desired clonal line can be isolated). See, e.g., Goding, MAbs: Principles and Practice, pp. 59-103, Academic Press, 1986.
  • MAbs secreted by these clonal cell lines can be purified from the culture medium or a bodily fluid (e.g., ascites) by conventional Ig purification procedures such as salt cuts, size exclusion, ion exchange separation, and affinity chromatography.
  • heterologous expression systems to produce mAbs. See, e.g., the methods described in U.S. patent application Ser. No. 11/754,899.
  • the genes encoding an mAb specific for human IL-1 ⁇ might be cloned and introduced into an expression vector (e.g., a plasmid-based expression vector) for expression in a heterologous host cell (e.g., CHO cells, COS cells, myeloma cells, and E. coli cells).
  • a heterologous host cell e.g., CHO cells, COS cells, myeloma cells, and E. coli cells.
  • Igs include heavy (H) and light (L) chains in an H 2 L 2 configuration
  • the genes encoding each may be separately isolated and expressed in different vectors.
  • chimeric mAbs e.g., “humanized” mAbs
  • Such chimeric Abs can be prepared by methods known in the art. See, e.g., Morrison et al., Proc. Nat'l. Acad. Sci. USA, 81:6851, 1984; Neuberger et al., Nature, 312:604, 1984; Takeda et al., Nature, 314:452, 1984.
  • Abs can be humanized by methods known in the art.
  • mAbs with a desired binding specificity can be humanized by various vendors or as described in U.S. Pat. Nos. 5,693,762; 5,530,101; or 5,585,089.
  • the mAbs described herein might be affinity matured to enhance or otherwise alter their binding specificity by known methods such as VH and VL domain shuffling (Marks et al. Bio/Technology 10:779-783, 1992), random mutagenesis of the hypervariable regions (HVRs) and/or framework residues (Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813, 1994; Schier et al. Gene 169:147-155, 1995; Yelton et al. J. Immunol. 155:1994-2004, 1995; Jackson et al., J. Immunol. 154(7):3310-9, 1995; and Hawkins et al, J. Mol. Biol.
  • Amino acid sequence variants of an Ab may be prepared by introducing appropriate changes into the nucleotide sequence encoding the Ab.
  • modifications to nucleic acid sequences encoding mAbs might be altered (e.g., without changing the amino acid sequence of the mAb) for enhancing production of the mAb in certain expression systems (e.g., intron elimination and/or codon optimization for a given expression system).
  • the mAbs described herein can also be modified by conjugation to another protein (e.g., another mAb) or non-protein molecule.
  • a mAb might be conjugated to a water soluble polymer such as polyethylene glycol or a carbon nanotube (See, e.g., Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605, 2005). See, U.S. patent application number 11/754,899.
  • a water soluble polymer such as polyethylene glycol or a carbon nanotube
  • the mAb compositions of the invention are at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, 99.9 or more percent by weight pure (excluding any excipients).
  • the mAb compositions of the invention might include only a single type of mAb (i.e., one produced from a single clonal B lymphocyte line) or might include a mixture of two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) different types of mAbs.
  • the human IL-1 ⁇ mAbs might be conjugated with another molecule such as a cytotoxin.
  • a human IL- 1 ⁇ specific mAb might be conjugated with one or more cytotoxins to more effectively kill cells expressing IL- 1 ⁇ .
  • Cytotoxins for use in the invention can be any cytotoxic agent (e.g., molecule that can kill a cell after contacting the cell) that can be conjugated to a human IL-1 ⁇ specific mAb.
  • cytotoxins include, without limitation, radionuclides (e.g., 35 S, 14 C, 32 P, 125 I, 131 I, 90 Y, 89 Zr, 201 Tl, 186 Re, 188 Re, 57 Cu, 213 Bi, and 211 At), conjugated radionuclides, and chemotherapeutic agents.
  • radionuclides e.g., 35 S, 14 C, 32 P, 125 I, 131 I, 90 Y, 89 Zr, 201 Tl, 186 Re, 188 Re, 57 Cu, 213 Bi, and 211 At
  • conjugated radionuclides e.g., chemotherapeutic agents.
  • cytotoxins include, but are not limited to, antimetabolites (e.g., 5-fluorouricil (5-FU), methotrexate (MTX), fludarabine, etc.), anti-microtubule agents (e.g., vincristine, vinblastine, colchicine, taxanes (such as paclitaxel and docetaxel), etc.), alkylating agents (e.g., cyclophasphamide, melphalan, bischloroethylnitrosurea (BCNU), etc.), platinum agents (e.g., cisplatin (also termed cDDP), carboplatin, oxaliplatin, JM-216, CI-973, etc.), anthracyclines (e.g., doxorubicin, daunorubicin, etc.), antibiotic agents (e.g., mitomycin-C), topoisomerase inhibitors (e.g., etoposide, tenoposide, and
  • IL-1 ⁇ specific Abs described above are preferred for use in the invention
  • other agents that specifically target IL- 1 ⁇ might be used so long as their administration leads to improvement of a characteristic of an inflammatory skin disease.
  • these other agents might include vaccines that cause the production of anti- IL-1 ⁇ Abs, proteins or peptides that bind IL-1 ⁇ , and small organic molecules which specifically target IL-1 ⁇ . Those that do not specifically bind other agents that specifically target IL-1 ⁇ are preferred.
  • the anti-IL-1 ⁇ Ab compositions may be administered to animals or humans in pharmaceutically acceptable carriers (e.g., sterile saline), that are selected on the basis of mode and route of administration and standard pharmaceutical practice.
  • pharmaceutically acceptable carriers e.g., sterile saline
  • a list of pharmaceutically acceptable carriers, as well as pharmaceutical formulations, can be found in Remington's Pharmaceutical Sciences, a standard text in this field, and in USP/NF.
  • Other substances may be added to the compositions and other steps taken to stabilize and/or preserve the compositions, and/or to facilitate their administration to a subject.
  • the Ab compositions might be lyophilized (see Draber et al., J. Immunol. Methods. 181:37, 1995; and PCT/US90/01383); dissolved in a solution including sodium and chloride ions; dissolved in a solution including one or more stabilizing agents such as albumin, glucose, maltose, sucrose, sorbitol, polyethylene glycol, and glycine; filtered (e.g., using a 0.45 and/or 0.2 micron filter); contacted with beta-propiolactone; and/or dissolved in a solution including a microbicide (e.g., a detergent, an organic solvent, and a mixture of a detergent and organic solvent.
  • a microbicide e.g., a detergent, an organic solvent, and a mixture of a detergent and organic solvent.
  • compositions may be administered to animals or humans by any suitable technique. Typically, such administration will be parenteral (e.g., intravenous, subcutaneous, intramuscular, or intraperitoneal introduction).
  • parenteral e.g., intravenous, subcutaneous, intramuscular, or intraperitoneal introduction
  • the compositions may also be administered directly to the target site (e.g., the skin) by, for example, topical application.
  • Other methods of delivery e.g., liposomal delivery or diffusion from a device impregnated with the composition, are known in the art.
  • the composition may be administered in a single bolus, multiple injections, or by continuous infusion (e.g., intravenously or by peritoneal dialysis).
  • a therapeutically effective amount is an amount which is capable of producing a medically desirable result in a treated animal or human.
  • An effective amount of anti-IL-1 ⁇ Ab compositions is an amount which shows clinical efficacy in patients as measured by the improvement in one or more symptoms of skin inflammation.
  • dosage for any one animal or human depends on many factors, including the subject's size, body surface area, age, the particular composition to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
  • Preferred doses range from about 0.1 to 5 (e.g., 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, or 6) mg/kg body weight.
  • a single dose is effective at resolving an episode of skin inflammation.
  • doses may be given repeatedly, e.g., semi-weekly, weekly, bi-weekly, tri-weekly, semi-monthly, once every three weeks, monthly, bi-monthly, or as needed (if skin inflammation recurs).
  • XilonixTM is a sterile injectable liquid formulation of 15 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4).
  • a stabilizing isotonic buffer pH 6.4.
  • Each 10-mL Type I borosilicate glass serum vial contains 5 mL of the formulation, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
  • the product is stored at 5 ⁇ 3° C., with excursions to room temperature permitted.
  • the exact composition of the drug product is shown below:
  • composition of the Drug Product (Xilonix TM) Ingredient Grade Manufacturer Concentration MABp1 Ab GMP XBiotech 15 mg/mL sodium phosphate dibasic compendial JT Baker 12 mg/mL citric acid monohydrate compendial JT Baker 2 mg/mL Trehalose•2H2O compendial Ferro- 60 mg/mL (high-purity low Pfanstiehl endotoxin) polysorbate 80 compendial JT Baker 0.2 mg/mL Phosphoric acid, to compendial JT Baker 0.04 mg/mL adjust pH water for injection compendial Microbix q.s.
  • the calculated volume is withdrawn from the drug (mAb)-containing vial(s) using a suitable syringe.
  • the drug is then injected into a subject subcutaneously.
  • the patient was observed for 2 hours post-infusion. There was no apparent infusion reaction, or adverse response to the drug. After 24-hours the patient was re-evaluated. Large lesions on the shoulder and back had dramatically reduced in size. Reduced inflammatory infiltration of facial lesions was evidenced by less redness of the lesions and reduced lesion sizes compared to pre-dose. The lesions appeared to be drying.
  • T2-18C3 is a sterile liquid formulation of 100 ⁇ 5 mg/mL MABp1 in a stabilizing isotonic formulation buffer (pH 6.4 ⁇ 0.1). 1.4 ⁇ 0.1 mL of this formulation was contained within two mL Type I borosilicate glass serum vials sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal. The product with stored upright at 5 ⁇ 3° C., with excursions to room temperature permitted. The exact composition of the Drug Product is shown below in Table 2:
  • T2-18C3 A 48-year old male with a history of Type I psoriasis vulgaris, diagnosed at age 5 was treated with T2-18C3.
  • the patient has a positive family history of psoriasis vulgaris, with his sibling, father, and grandmother being affected as well. He was previously treated with topical retinoids and vitamin D3 preparations with minimal improvement. Previous treatment with topical steroids and UV treatment showed benefit. Prior to administration of T2-18C3, the patient had no history of treatment with biologic agents.
  • the patient was administered 2 subcutaneous injections of MABp1 in the lower abdomen (a total of 160 mg MABp1) on day 0.
  • the patient tolerated the injections well, and there were no complications.
  • the patient's back was evaluated at 17 hours, 41 hours, 5 days, 6 days and 10 days post-administration.
  • 17 hours a modest improvement in the redness associated with the lesions was observed.
  • 41 hours continued improvement was noted with a clearly observable decrease in the size and redness of the lesions.
  • significant resolution of the lesions was observed. This improvement continued through day 6.
  • the lesions were almost completely resolved by day 10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/437,159 2011-04-01 2012-04-02 Treatment of Dermatological Pathologies Abandoned US20120251548A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/437,159 US20120251548A1 (en) 2011-04-01 2012-04-02 Treatment of Dermatological Pathologies
US13/644,976 US9724409B2 (en) 2011-04-01 2012-10-04 Treatment of inflammatory skin disease
US13/928,020 US20130287788A1 (en) 2011-04-01 2013-06-26 Treatment of Psychiatric Conditions
US15/252,477 US9902769B2 (en) 2011-04-01 2016-08-31 Treatment of dermatological pathologies
US16/112,496 US11191831B2 (en) 2011-04-01 2018-08-24 Treatment of psychiatric conditions
US17/453,894 US20220062413A1 (en) 2011-04-01 2021-11-08 Treatment of psychiatric conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470538P 2011-04-01 2011-04-01
US13/437,159 US20120251548A1 (en) 2011-04-01 2012-04-02 Treatment of Dermatological Pathologies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/644,976 Continuation-In-Part US9724409B2 (en) 2011-04-01 2012-10-04 Treatment of inflammatory skin disease
US15/252,477 Continuation US9902769B2 (en) 2011-04-01 2016-08-31 Treatment of dermatological pathologies

Publications (1)

Publication Number Publication Date
US20120251548A1 true US20120251548A1 (en) 2012-10-04

Family

ID=46927554

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/437,159 Abandoned US20120251548A1 (en) 2011-04-01 2012-04-02 Treatment of Dermatological Pathologies
US15/252,477 Active US9902769B2 (en) 2011-04-01 2016-08-31 Treatment of dermatological pathologies

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/252,477 Active US9902769B2 (en) 2011-04-01 2016-08-31 Treatment of dermatological pathologies

Country Status (11)

Country Link
US (2) US20120251548A1 (enrdf_load_stackoverflow)
EP (2) EP3417879A1 (enrdf_load_stackoverflow)
JP (2) JP6062918B2 (enrdf_load_stackoverflow)
KR (3) KR102326482B1 (enrdf_load_stackoverflow)
CN (2) CN110201157A (enrdf_load_stackoverflow)
AU (2) AU2012236106B2 (enrdf_load_stackoverflow)
CA (1) CA2831126C (enrdf_load_stackoverflow)
DK (1) DK2694107T3 (enrdf_load_stackoverflow)
ES (1) ES2697056T3 (enrdf_load_stackoverflow)
PT (1) PT2694107T (enrdf_load_stackoverflow)
WO (1) WO2012135812A2 (enrdf_load_stackoverflow)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160368982A1 (en) * 2011-04-01 2016-12-22 Xbiotech, Inc. Treatment of Dermatological Pathologies
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US11191831B2 (en) 2011-04-01 2021-12-07 Janssen Biotech, Inc. Treatment of psychiatric conditions
US11390672B2 (en) 2010-06-18 2022-07-19 Janssen Biotech, Inc. Arthritis treatment
US11932688B2 (en) 2010-08-23 2024-03-19 Xbiotech Inc. Treatment for neoplastic diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2903643A4 (en) * 2012-10-04 2016-06-15 Xbiotech Inc TREATMENT OF PSYCHIATRIC DISEASES
WO2021211927A1 (en) * 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
CA3095675A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
WO1994008624A2 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5945576A (en) * 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Ｖｐｌｆの活性を阻害する抗体
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
EP2326347A4 (en) * 2008-09-12 2013-03-06 Xbiotech Inc TARGETING ILLNESSING MONOCYTES
JP2012516153A (ja) * 2009-01-29 2012-07-19 アボット・ラボラトリーズ Ｉｌ−１結合タンパク質
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
JP6062918B2 (ja) * 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390672B2 (en) 2010-06-18 2022-07-19 Janssen Biotech, Inc. Arthritis treatment
US12116405B2 (en) 2010-06-18 2024-10-15 Xbiotech Inc. Arthritis treatment
US11932688B2 (en) 2010-08-23 2024-03-19 Xbiotech Inc. Treatment for neoplastic diseases
US20160368982A1 (en) * 2011-04-01 2016-12-22 Xbiotech, Inc. Treatment of Dermatological Pathologies
US9902769B2 (en) * 2011-04-01 2018-02-27 Xbiotech, Inc. Treatment of dermatological pathologies
US11191831B2 (en) 2011-04-01 2021-12-07 Janssen Biotech, Inc. Treatment of psychiatric conditions
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US11225517B2 (en) 2017-02-16 2022-01-18 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
AU2017201201B2 (en) 2018-12-13
JP2014509662A (ja) 2014-04-21
CN103442733A (zh) 2013-12-11
EP3417879A1 (en) 2018-12-26
WO2012135812A3 (en) 2013-01-31
WO2012135812A2 (en) 2012-10-04
ES2697056T3 (es) 2019-01-21
EP2694107A2 (en) 2014-02-12
EP2694107A4 (en) 2014-10-01
EP2694107B1 (en) 2018-08-22
KR20200145844A (ko) 2020-12-30
AU2012236106B2 (en) 2016-12-08
US9902769B2 (en) 2018-02-27
KR20190090046A (ko) 2019-07-31
CA2831126A1 (en) 2012-10-04
JP2017014228A (ja) 2017-01-19
AU2017201201A1 (en) 2017-04-06
KR102326482B1 (ko) 2021-11-17
US20160368982A1 (en) 2016-12-22
PT2694107T (pt) 2018-11-27
DK2694107T3 (en) 2018-12-10
JP6453278B2 (ja) 2019-01-16
KR102004554B1 (ko) 2019-10-01
CN110201157A (zh) 2019-09-06
KR20140033036A (ko) 2014-03-17
AU2012236106A1 (en) 2013-09-26
JP6062918B2 (ja) 2017-01-18
CA2831126C (en) 2019-11-12

Similar Documents

Publication Publication Date Title
US11191831B2 (en) Treatment of psychiatric conditions
US9902769B2 (en) Treatment of dermatological pathologies
US12116405B2 (en) Arthritis treatment
CA2886757C (en) Treatment of anxiety with il1.alpha. antagonist
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
AS Assignment

Owner name: XBIOTECH, INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIMARD, JOHN;REEL/FRAME:028208/0536

Effective date: 20120504

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: JANSSEN BIOTECH, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:XBIOTECH INC.;REEL/FRAME:051769/0927

Effective date: 20191230